DM Capital

Convo Advanced Manufacturing is a reliable platform for biomanufacturing technology. It works to develop an integrated global biomanufacturing technology, tools, goods, and services.

MimiX Biotherapeutics Sàrl is a Swiss company founded in 2016 that specializes in biofabrication technology focused on tissue manufacturing for therapeutic and diagnostic applications. Based in La Tène, the company aims to revolutionize regenerative and personalized medicine through its innovative point-of-care approach. By developing ultra-fast biomanufacturing technology, MimiX Biotherapeutics seeks to create patient-specific biological tissue equivalents, facilitating tailored treatments that meet individual medical needs.

Rege Nephro is a Kyoto-based biotechnology company focused on renal disease therapeutics. It conducts research and development, production, and marketing of therapies based on nephron progenitor cells, and develops kidney organoids used to screen nephrotoxicity in drug discovery. The company is leveraging induced pluripotent stem cell technology from the Center for iPS Cell Research and Application at Kyoto University to develop cell-based therapies for kidney conditions, along with potential applications for liver and pancreas diseases. Founded in 2019, Rege Nephro aims to reduce dialysis dependence by addressing renal failure through regenerative approaches.

Huayuan Regenerative Medicine is the manufacture of implantable bioartificial organs. Huayuan Regenerative Medicine is committed to the research and development, production, and sales of clinical grade stem cells, biological tissue engineering products, and biomanufacturing. Their clinical products include urinary kidney precursor cells, dialysis equipment, and a biosynthetic artificial pancreas.

Shang Gong is a Beijing Based Healthcare Start Up.

Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing functional cures for patients with chronic diseases. Founded in 2015, the company aims to create immune-protected, engineered human cells that restore normal physiological functions without the risk of fibrosis or immune rejection. Its lead product candidate, SIG-001, is currently in Phase I/II clinical trials for preventing bleeding episodes in patients with moderate to severe Hemophilia A. Additionally, Sigilon is advancing other candidates, including SIG-005, which targets non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells for treating type 1 diabetes. The company's innovative Shielded Living Therapeutics platform leverages advances in cell engineering and proprietary biocompatible materials to offer stable and durable therapeutic solutions for a variety of chronic conditions.

IVIVA Medical, Inc. is a biotechnology company based in Beverly, Massachusetts, focused on developing innovative therapies for end-stage renal disease (ESRD). Founded in 2013, the company aims to address the critical shortage of donor organs by creating autologous tissue constructs that provide alternative treatments for patients suffering from this condition, which affects over 500,000 individuals in the United States. IVIVA Medical leverages advanced technologies in tissue engineering, 3D additive manufacturing, and stem cell biology to create bioartificial platforms and systems. These platforms not only facilitate therapeutic applications but also serve as essential building blocks for the next generation of engineered, functionalized tissues, positioning IVIVA Medical at the forefront of regenerative medicine and enhancing the capacity of medical professionals to manage end-stage kidney disease.

uLab Systems Inc. is a technology company specializing in digital dental treatment planning for orthodontists. Established in 2015 and headquartered in Redwood City, California, with an additional office in Shanghai, China, uLab has developed a sophisticated software platform that allows orthodontists to create customized treatment plans and aligner movement strategies. The company's proprietary technology employs artificial intelligence and fully automated features, enabling orthodontists to efficiently generate chairside treatment plans in under five minutes. This innovation not only streamlines the treatment process but also helps in reducing lab fees and expediting the delivery of custom aligners. Through its solutions, uLab Systems enhances the efficiency and effectiveness of orthodontic care.

eBrace is a company focused on the research, development, and production of digital 3D printing technology specifically tailored for orthodontics. The firm specializes in creating innovative solutions for dental applications, including bracketless invisible appliances, customized lingual invisible appliances, and dentures. By leveraging advanced 3D printing techniques, eBrace aims to deliver precise and detailed dental products that meet the needs of both practitioners and patients.

Jiahong DentalLab specializes in manufacturing and distributing a wide range of dental products and services. Their offerings include both fixed and removable dentures, orthodontic products, and other dental equipment. Notably, they provide advanced solutions such as CNC-pure titanium brackets, implant suprabridges, and zirconia all-ceramic bridges, catering to both aesthetic and functional needs. Additionally, they offer dental restoration services, enabling patients to enhance their dental and oral health.